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Abstract
OX40 is a potent co-stimulatory receptor on the surface of
T lymphocytes. An OX40 agonist was recently tested in a
Phase I clinical trial and was found to be well tolerated
and enhanced both humoral and cellular immunity in
patients with metastatic cancer. Both PD-1 and CTLA-4
blockade are showing therapeutic clinical activity in late
stage cancer patients. Hence, we hypothesize that the
immune suppressed tumor microenvironment that char-
acterizes oral, head and neck squamous cell carcinoma
(OHNSCC) can be overcome by strategies that favor anti-
tumor inflammatory T cell responses and may be an ideal
tumor site for immune modulation. This investigation
aims to provide a better understanding of the expression
of OX40, PD-1, CTLA-4 and CD103 in OHNSCC tumor
infiltrating lymphocytes (TIL). Additionally we evaluated
whether phenotypic differences existed in patients with
HPV positive vs. negative status.
Methods
TIL and autologous blood were isolated from 29 patients
undergoing surgery for OHNSCC. A sample of tissue was
obtained from the resection specimen of the primary
tumor and sent to the laboratory with autologous blood.
Tumor was minced and subjected to digestive enzymes.
Blood and tumor samples were separated over ficoll gradi-
ent to enrich for lymphocytes. Samples were frozen at
-140°c and later thawed in batches for analysis. Proteins
were then labeled with fluorescently conjugated antibodies
and analyzed by flow cytometry.
Results
The percentage of FoxP3+CD25+CD4+ (Tregs) of CD4+
T cells is significantly higher in OHNSCC Tumor Infil-
trating Lymphocytes (TIL) compared to blood (p <
.0005), regardless of HPV status. OX40 expression is sig-
nificantly higher in the TIL Treg population relative to
blood Tregs (p < .0005), also independent of HPV status.
PD1 expression is increased in the Tregs (p < .0005), con-
ventional CD4 (p=.0066), and CD8 T cells (p < .0005), in
TIL relative to blood. CTLA-4 expression is increased in
TIL relative to blood in all subsets with the highest
expression observed in the Treg population (.0056).
CD103 expression is increased on CD8 T cells in TIL
relative to blood (p < .0005). CD8s from HPV positive
patients have higher percentage CD103 positive cells
than CD8s from HPV negative patients (p=.0056). The
highest percentages of PD-1, CTLA-4 and OX40 triple
positive cells were found in the Treg population of TIL
compared to blood (p < .0005). Due to increased expres-
sion of OX40, CTLA-4 and PD-1 in TIL of OHNSCC
patients we hypothesize that future combination clinical
trials that target these pathways will be therapeutically
beneficial.
Authors’ details
1Agonox, Inc, Portland, OR, USA. 2Providence Cancer Center, Portland, OR,
USA. 3The Oregon Clinic, Portland, OR, USA.
Published: 6 November 2014
doi:10.1186/2051-1426-2-S3-P113
Cite this article as: Montler et al.: OX40 and other immunoregulatory
molecules are highly expressed on tumor infiltrating lymphocytes in oral,
head and neck squamous cell carcinoma. Journal for ImmunoTherapy of
Cancer 2014 2(Suppl 3):P113.
1Agonox, Inc, Portland, OR, USA
Full list of author information is available at the end of the article
Montler et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P113
http://www.immunotherapyofcancer.org/content/2/S3/P113
© 2014 Montler et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
